Literature DB >> 35976392

Fully automatic prognostic biomarker extraction from metastatic prostate lesion segmentations in whole-body [68Ga]Ga-PSMA-11 PET/CT images.

Jake Kendrick1, Roslyn J Francis2,3, Ghulam Mubashar Hassan4, Pejman Rowshanfarzad4, Jeremy S L Ong5, Martin A Ebert4,6,7.   

Abstract

PURPOSE: This study aimed to develop and assess an automated segmentation framework based on deep learning for metastatic prostate cancer (mPCa) lesions in whole-body [68Ga]Ga-PSMA-11 PET/CT images for the purpose of extracting patient-level prognostic biomarkers.
METHODS: Three hundred thirty-seven [68Ga]Ga-PSMA-11 PET/CT images were retrieved from a cohort of biochemically recurrent PCa patients. A fully 3D convolutional neural network (CNN) is proposed which is based on the self-configuring nnU-Net framework, and was trained on a subset of these scans, with an independent test set reserved for model evaluation. Voxel-level segmentation results were assessed using the dice similarity coefficient (DSC), positive predictive value (PPV), and sensitivity. Sensitivity and PPV were calculated to assess lesion level detection; patient-level classification results were assessed by the accuracy, PPV, and sensitivity. Whole-body biomarkers total lesional volume (TLVauto) and total lesional uptake (TLUauto) were calculated from the automated segmentations, and Kaplan-Meier analysis was used to assess biomarker relationship with patient overall survival.
RESULTS: At the patient level, the accuracy, sensitivity, and PPV were all > 90%, with the best metric being the PPV (97.2%). PPV and sensitivity at the lesion level were 88.2% and 73.0%, respectively. DSC and PPV measured at the voxel level performed within measured inter-observer variability (DSC, median = 50.7% vs. second observer = 32%, p = 0.012; PPV, median = 64.9% vs. second observer = 25.7%, p < 0.005). Kaplan-Meier analysis of TLVauto and TLUauto showed they were significantly associated with patient overall survival (both p < 0.005).
CONCLUSION: The fully automated assessment of whole-body [68Ga]Ga-PSMA-11 PET/CT images using deep learning shows significant promise, yielding accurate scan classification, voxel-level segmentations within inter-observer variability, and potentially clinically useful prognostic biomarkers associated with patient overall survival. TRIAL REGISTRATION: This study was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12615000608561) on 11 June 2015.
© 2022. The Author(s).

Entities:  

Keywords:  Deep learning; PET/CT; PSMA; Prognostic biomarkers; Prostate cancer; Segmentation

Year:  2022        PMID: 35976392     DOI: 10.1007/s00259-022-05927-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   10.057


  30 in total

Review 1.  PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.

Authors:  Hans-Jürgen Wester; Margret Schottelius
Journal:  Semin Nucl Med       Date:  2019-04-30       Impact factor: 4.446

2.  A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.

Authors:  Michael McCarthy; Roslyn Francis; Colin Tang; Joanne Watts; Andrew Campbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-16       Impact factor: 7.038

Review 3.  Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.

Authors:  Jan Norum; Carsten Nieder
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

4.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.

Authors:  G L Wright; C Haley; M L Beckett; P F Schellhammer
Journal:  Urol Oncol       Date:  1995 Jan-Feb       Impact factor: 3.498

Review 5.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Authors:  Arundhati Ghosh; Warren D W Heston
Journal:  J Cell Biochem       Date:  2004-02-15       Impact factor: 4.429

Review 6.  Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates.

Authors:  MaryBeth B Culp; Isabelle Soerjomataram; Jason A Efstathiou; Freddie Bray; Ahmedin Jemal
Journal:  Eur Urol       Date:  2019-09-05       Impact factor: 20.096

7.  The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-20       Impact factor: 9.236

Review 8.  Biochemical recurrence after radical prostatectomy: what does it mean?

Authors:  Rafael Tourinho-Barbosa; Victor Srougi; Igor Nunes-Silva; Mohammed Baghdadi; Gregory Rembeyo; Sophie S Eiffel; Eric Barret; Francois Rozet; Marc Galiano; Xavier Cathelineau; Rafael Sanchez-Salas
Journal:  Int Braz J Urol       Date:  2018 Jan-Feb       Impact factor: 1.541

9.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Journal:  N Engl J Med       Date:  2021-06-23       Impact factor: 91.245

10.  Survival after bone metastasis by primary cancer type: a Danish population-based cohort study.

Authors:  Elisabeth Svensson; Christian F Christiansen; Sinna P Ulrichsen; Mikael R Rørth; Henrik T Sørensen
Journal:  BMJ Open       Date:  2017-09-11       Impact factor: 2.692

View more
  1 in total

Review 1.  A review of artificial intelligence in prostate cancer detection on imaging.

Authors:  Indrani Bhattacharya; Yash S Khandwala; Sulaiman Vesal; Wei Shao; Qianye Yang; Simon J C Soerensen; Richard E Fan; Pejman Ghanouni; Christian A Kunder; James D Brooks; Yipeng Hu; Mirabela Rusu; Geoffrey A Sonn
Journal:  Ther Adv Urol       Date:  2022-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.